Search results for "AMINO ACID"

showing 10 items of 3965 documents

The Clinical Relevance of LDL Size and Subclasses Modulation in Patients with Type-2 Diabetes

2007

increasing evidence suggest that the "quality" rather than only the "quantity" of low density lipoproteins (LDL) exerts a great influence on the cardiovascular risk. Hypertriglyceridemia, low HDL-cholesterol and increased levels of small dense LDL characterise diabetic dyslipidemia. in subjects with type-2 diabetes LDL size seems also to represent a good marker of clinical apparent and non-apparent atherosclerosis. Recently, the Coordinating Committee of the National Cholesterol Education Program stated that high-risk patients may benefit of stronger therapeutical approaches, a category of subjects that include those with type-2 diabetes. Screening for the presence of small, dense LDL may p…

medicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismAtorvastatinPharmacologyEndocrinologyEzetimibeInternal medicineInternal MedicineHumansMedicineGemfibrozilCholesterol absorption inhibitorNational Cholesterol Education ProgramHypolipidemic Agentssmall dense LDL subclasses fibrates statins ezetimibe diabetes high-riskFenofibrateBezafibratebusiness.industryHypertriglyceridemiaGeneral Medicinemedicine.diseaseLipoproteins LDLMolecular WeightEndocrinologyDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)businessmedicine.drugExperimental and Clinical Endocrinology & Diabetes
researchProduct

The role of fibrate treatment in dyslipidemia: an overview.

2012

Dyslipidemia, and especially atherogenic dyslipidemia, a combination of small low-density lipoproteins cholesterol (LDL-C), decreased high-density lipoprotein cholesterol (HDL-C) and increased triglyceride (TG) concentrations, represents a major cardiovascular (CV) risk factor. Nuclear receptor peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid metabolism; PPAR ligands are used to treat dyslipidemias. Fibrates have a major impact on TG metabolism as well as on modulating LDL size and subclasses. Fibrates target atherogenic dyslipidemia by increasing plasma HDL-C concentrations and decreasing small dense LDL (sdLDL) particles and TGs, thus contributin…

medicine.medical_specialtymedicine.drug_classPeroxisome proliferator-activated receptorAdipokineFibratechemistry.chemical_compoundInternal medicineDrug DiscoverymedicineAnimalsHumansTriglyceridesDyslipidemiasHypolipidemic AgentsPharmacologychemistry.chemical_classificationTriglycerideCholesterolbusiness.industryFibric Acidsnutritional and metabolic diseasesLipid metabolismCholesterol LDLmedicine.diseaseFibrates dyslipidemia cardiovascular risk diabetes.EndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Metabolic syndromebusinessDyslipidemiaCurrent pharmaceutical design
researchProduct

CHF2819: Pharmacological profile of a novel acetylcholinesterase inhibitor

2002

CHF2819 is a novel orally active acetylcholinesterase inhibitor (AChEI) developed for the treatment of Alzheimer's disease (AD). CHF2819 is a selective inhibitor of AChE, it is 115 times more potent against this enzyme than against butyrylcholinesterase (BuChE). Moreover, CHF2819 is more selective for inhibition of central (brain) AChE than peripheral (heart) AChE. In vivo CHF2819, 0.5, 1.5, and 4.5 mg/kg p.o., significantly and in dose-dependent manner increased acetylcholine (ACh) levels in hippocampus of young adult rats. Moreover, aging animals, with lower basal ACh levels than young adult rats, also exhibit a marked increase in hippocampal levels of this neurotransmitter after administ…

medicine.medical_specialtymedicine.drug_classPhenylcarbamatesPharmacologyHippocampusArticleCyclic N-Oxideschemistry.chemical_compoundNeurochemicalAlzheimer DiseaseDopamineInternal medicinemedicineAnimalsBiogenic MonoaminesAmino AcidsNeurotransmitterButyrylcholinesteraseCholinesterasePharmacologybiologybusiness.industryGlutamate receptoracetylcholinesterase inhibitors; alzheimer's disease; amino acids; chf2819; ganstigmine; neurotransmitters; rat hippocampusAcetylcholineRatsNeuropsychology and Physiological PsychologyEndocrinologyAcetylcholinesterase inhibitorchemistrybiology.proteinCarbamatesCholinesterase InhibitorsbusinessAcetylcholinemedicine.drug
researchProduct

Constitutive androstane receptor activation stimulates faecal bile acid excretion and reverse cholesterol transport in mice.

2010

The constitutive androstane receptor (CAR) is a nuclear receptor expressed in the liver and involved in xenobiotic metabolism. The aim of this study was to assess whether pharmacological CAR activation could affect neutral sterol and bile acid elimination under conditions of cholesterol overload.Wild type, Car-/-, ApoE-/-, and low-density lipoprotein receptor (Ldlr)-/- mice fed a western-type diet were treated with the CAR agonist TCPOBOP.CAR activation was associated with a decrease in faecal cholesterol output related to the repression of the Abcg5/g8 cholesterol transporters. In contrast, TCPOBOP treatment induced a marked increase (up to three fold, p0.01) in the elimination of faecal b…

medicine.medical_specialtymedicine.drug_classPyridinesLipoproteinsBiological Transport ActiveGene ExpressionReceptors Cytoplasmic and NuclearHyperlipidemiasBiologyCholesterol 7 alpha-hydroxylaseBile Acids and Saltschemistry.chemical_compoundFecesMiceApolipoproteins EInternal medicineConstitutive androstane receptormedicineAnimalsHomeostasisATP Binding Cassette Transporter Subfamily G Member 5Liver X receptorConstitutive Androstane ReceptorMice KnockoutHepatologyBile acidCholesterolReverse cholesterol transportATP Binding Cassette Transporter Subfamily G Member 8Cholesterol HDLAtherosclerosisSterolMice Inbred C57BLEndocrinologyCholesterolchemistryLiverReceptors LDLLDL receptorlipids (amino acids peptides and proteins)ATP-Binding Cassette TransportersJournal of hepatology
researchProduct

Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal Neurons

2009

Metabotropic glutamate (mGlu) receptors have been considered potential targets for the therapy of experimental parkinsonism. One hypothetical advantage associated with the use of mGlu receptor ligands is the lack of the adverse effects typically induced by ionotropic glutamate receptor antagonists, such as sedation, ataxia, and severe learning impairment. Low doses of the mGlu2/3 metabotropic glutamate receptor agonist, LY379268 (0.25-3 mg/kg, i.p.) increased glial cell line-derived neurotrophic factor (GDNF) mRNA and protein levels in the mouse brain, as assessed by in situ hybridization, real-time PCR, immunoblotting, and immunohistochemistry. This increase was prominent in the striatum, …

medicine.medical_specialtymedicine.drug_classlcsh:MedicineSubstantia nigraReceptors Metabotropic GlutamateSettore BIO/09 - FisiologiaPolymerase Chain ReactionMiceNeurotrophic factorsInternal medicinemedicineGlial cell line-derived neurotrophic factorAnimalsGlial Cell Line-Derived Neurotrophic FactorRNA MessengerAmino Acidslcsh:ScienceReceptorIn Situ HybridizationNeurological Disorders/Movement DisordersNeuronsMultidisciplinarybiologyNeuroscience/Neuronal and Glial Cell Biologylcsh:RGlutamate receptorBridged Bicyclo Compounds HeterocyclicReceptor antagonistCorpus StriatumEndocrinologyMetabotropic receptornervous systemMetabotropic glutamate receptorSettore BIO/14 - Farmacologiabiology.proteinlcsh:QNeuroscience/Neurobiology of Disease and RegenerationReceptors Metabotropic Glutamate/agonists Glial Cell Line-Derived Neurotrophic FactorResearch Article
researchProduct

Induction of dendritic cell maturation and modulation of dendritic cell-induced immune responses by prostaglandins

2000

Dendritic cells (DC) are the most potent antigen-presenting cells of the immune system. In this study we investigated the effects of various prostaglandins (PG) on the stimulatory capacity of DC. DC were generated from peripheral progenitor cells in the presence of IL-4 and GM-CSF and stimulated with IL-1, IL-6 and TNF-alpha on day 7. Simultaneously, PG (PGD(2), PGE(1), PGE(2), PGF(2 alpha), PGI(2)) were added at various concentrations (10(-5) to 10(-9) M) on day 7. In all experiments, PGE(2) had the most potent influence on the maturation of the DC, followed by other PG in the order PGE(1) > PGD(2) > PGF(2 alpha) > PGI(2). In addition, the expression of the surface molecules CD40, CD54, CD…

medicine.medical_specialtymedicine.medical_treatmentDermatologyLymphocyte ActivationProinflammatory cytokinechemistry.chemical_compoundInterferon-gammaAntigens CDInternal medicinemedicineHumansCells CulturedMHC class IIForskolinCD40biologyDose-Response Relationship DrugInterleukin-6Prostaglandin D2Tumor Necrosis Factor-alphaColforsinCell DifferentiationGeneral MedicineDendritic cellDendritic CellsMolecular biologyInterleukin-12Coculture TechniquesEndocrinologyCytokinechemistryBucladesinebiology.proteinProstaglandinsCytokinesInterleukin-2lipids (amino acids peptides and proteins)CD80CD8Interleukin-1
researchProduct

Effects of dietary conjugated linoleic acids in the control of adiposity and obesity‐related disorders

2007

The body fat-lowering effect of conjugated linoleic acids (CLA) in experimental animals has attracted much interest because of the potential use of CLA as weight loss agents in humans. The objective of this review was to give an overview of the results from human intervention trials. The review also addresses experimental studies in animal models and in cultured cells. CLA appear to provoke fat mass loss and an increase of fat-free mass in rodents, but the results in humans are inconsistent and much less clear than in rodents. Thus, the results of studies in humans do not support a body fat-lowering effect of CLA. There are indications from animal studies that the trans-10, cis-12 CLA isome…

medicine.medical_specialtymedicine.medical_treatmentLinoleic acidConjugated linoleic acidBiologyIndustrial and Manufacturing Engineeringchemistry.chemical_compoundInsulin resistanceLiver steatosisInternal medicinemedicinechemistry.chemical_classificationintegumentary systemInsulinfood and beveragesGeneral Chemistrymedicine.diseaseObesityEndocrinologyBiochemistrychemistrylipids (amino acids peptides and proteins)Animal studiesFood ScienceBiotechnologyPolyunsaturated fatty acidEuropean Journal of Lipid Science and Technology
researchProduct

Cholesterol as stabilizer of the oxytocin receptor

2002

AbstractThe function of the oxytocin receptor system is strongly dependent on steroids as demonstrated by several physiological studies. One key element of this dependence on steroids may be the interaction of cholesterol and the oxytocin receptor. In this study, we show that cholesterol stabilizes the solubilized human oxytocin receptor against thermal inactivation and proteolytic degradation. In the absence of additional cholesterol, the soluble receptor inactivates within minutes. Maximal stabilization of the oxytocin receptor requires a continuous supply with cholesterol from a cholesterol-rich environment. A structure–activity analysis of various cholesterol analogues and their effect …

medicine.medical_specialtymedicine.medical_treatmentProteolysisGreen Fluorescent ProteinsBiophysicsTransfectionBiochemistrySteroidCell Linechemistry.chemical_compoundInternal medicineEndopeptidasesmedicineHumansDenaturation (biochemistry)ReceptorOxytocin receptormedicine.diagnostic_testCholesterolTemperatureTransfectionCell BiologyHydrogen-Ion ConcentrationOxytocin receptorDenaturationLuminescent ProteinsEndocrinologyCholesterolchemistrySolubilityCell cultureReceptors OxytocinProteolysislipids (amino acids peptides and proteins)hormones hormone substitutes and hormone antagonistsBiochimica et Biophysica Acta (BBA) - Biomembranes
researchProduct

Cholesterol accumulation is increased in macrophages of phospholipid transfer protein-deficient mice: normalization by dietary alpha-tocopherol suppl…

2007

Objective— Phospholipid transfer protein (PLTP) is a multifunctional, extracellular lipid transport protein that plays a major role in lipoprotein metabolism and atherosclerosis. Recent in vivo studies suggested that unlike systemic PLTP, macrophage-derived PLTP would be antiatherogenic. The present study aimed at characterizing the atheroprotective properties of macrophage-derived PLTP. Methods and Results— Peritoneal macrophages were isolated from PLTP-deficient and wild-type mice and their biochemical characteristics were compared. It is shown that macrophages isolated from PLTP-deficient mice have increased basal cholesterol content and accumulate more cholesterol in the presence of LD…

medicine.medical_specialtymedicine.medical_treatmentalpha-TocopherolOxidative phosphorylationBiologychemistry.chemical_compoundMiceIn vivoPhospholipid transfer proteinInternal medicineMalondialdehydeExtracellularmedicineAnimalsTocopherolPhospholipid Transfer ProteinsMice KnockoutCholesterolVitamin EVitaminsLipoproteins LDLEndocrinologyCholesterolchemistryBiochemistryDietary SupplementsMacrophages Peritoneallipids (amino acids peptides and proteins)Cardiology and Cardiovascular Medicinealpha-TocopherolArteriosclerosis, thrombosis, and vascular biology
researchProduct

The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes.

1998

The disappointing clinical results of cancer immunotherapy of the past few decades have not diminished the optimism about the potential of the new generation of immunotherapeutic strategies towards treatment of malignant disease. Tremendous progress has been made over recent years in unveiling the molecular basis of antigen presentation and recognition by cytotoxic T lymphocytes (CTL). The molecular concepts that have emerged from these studies have led to the design of novel anticancer vaccines and CTL-based immunotherapeutics. This review is to highlight the current molecular insights of antigen presentation and CTL recognition/activation, and their impact on the rational design of therap…

medicine.medical_treatmentAntigen presentationMolecular Sequence Datachemical and pharmacologic phenomenaCancer VaccinesImmune systemCancer immunotherapyNeoplasmsDrug DiscoverymedicineCytotoxic T cellAnimalsHumansAmino Acid SequenceGenetics (clinical)Antigen Presentationbusiness.industryImmunotherapyT lymphocyteMolecular medicineCTL*ImmunologyMolecular MedicineImmunotherapybusinessT-Lymphocytes CytotoxicJournal of molecular medicine (Berlin, Germany)
researchProduct